Phase I study of atevirdine, a nonnucleoside reverse transcriptase inhibitor, in combination with zidovudine for human immunodeficiency virus type 1 infection

R. C. Reichman, G. D. Morse, L. M. Demeter, L. Resnick, Y. Bassiakos, Margaret A Fischl, M. Para, W. Powderly, J. Leedom, C. Greisberger, T. Nevin, K. Wood, P. M. Meehan, H. Geheb, S. Cox, D. Batts, J. Timpone, A. Slack, M. Royal

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Twenty patients were enrolled in a phase I clinical trial of atevirdine, a nonnucleoside reverse transcriptase inhibitor (NNRTI), given in combination with zidovudine for treatment of human immunodeficiency virus type 1 (HIV-1) infection. Fifteen patients had received no previous antiretroviral therapy. HIV-1 isolates obtained at 6-week intervals were tested for sensitivity to atevirdine and zidovudine. Two patients developed a rash within 2 weeks of enrollment, and 1 of these developed concomitant fever and hepatitis. No hematopoietic, neurologic, or pancreatic toxicities were observed. Atevirdine had considerable initial interpatient pharmacokinetic variability. Forty- seven percent of patients treated with atevirdine plus zidovudine had increased CD4 lymphocyte counts, and HIV isolates from 62% of patients remained sensitive to atevirdine after 24 weeks of therapy. Atevirdine plus zidovudine was well-tolerated. Additional studies should be done to determine the role of atevirdine in the therapy for HIV infection.

Original languageEnglish
Pages (from-to)297-304
Number of pages8
JournalJournal of Infectious Diseases
Volume171
Issue number2
StatePublished - Jan 1 1995

Fingerprint

Reverse Transcriptase Inhibitors
Zidovudine
Virus Diseases
HIV-1
Clinical Trials, Phase I
Therapeutics
CD4 Lymphocyte Count
atevirdine
Exanthema
Nervous System
Hepatitis
HIV Infections
Fever
Pharmacokinetics
HIV

ASJC Scopus subject areas

  • Immunology
  • Public Health, Environmental and Occupational Health

Cite this

Phase I study of atevirdine, a nonnucleoside reverse transcriptase inhibitor, in combination with zidovudine for human immunodeficiency virus type 1 infection. / Reichman, R. C.; Morse, G. D.; Demeter, L. M.; Resnick, L.; Bassiakos, Y.; Fischl, Margaret A; Para, M.; Powderly, W.; Leedom, J.; Greisberger, C.; Nevin, T.; Wood, K.; Meehan, P. M.; Geheb, H.; Cox, S.; Batts, D.; Timpone, J.; Slack, A.; Royal, M.

In: Journal of Infectious Diseases, Vol. 171, No. 2, 01.01.1995, p. 297-304.

Research output: Contribution to journalArticle

Reichman, RC, Morse, GD, Demeter, LM, Resnick, L, Bassiakos, Y, Fischl, MA, Para, M, Powderly, W, Leedom, J, Greisberger, C, Nevin, T, Wood, K, Meehan, PM, Geheb, H, Cox, S, Batts, D, Timpone, J, Slack, A & Royal, M 1995, 'Phase I study of atevirdine, a nonnucleoside reverse transcriptase inhibitor, in combination with zidovudine for human immunodeficiency virus type 1 infection', Journal of Infectious Diseases, vol. 171, no. 2, pp. 297-304.
Reichman, R. C. ; Morse, G. D. ; Demeter, L. M. ; Resnick, L. ; Bassiakos, Y. ; Fischl, Margaret A ; Para, M. ; Powderly, W. ; Leedom, J. ; Greisberger, C. ; Nevin, T. ; Wood, K. ; Meehan, P. M. ; Geheb, H. ; Cox, S. ; Batts, D. ; Timpone, J. ; Slack, A. ; Royal, M. / Phase I study of atevirdine, a nonnucleoside reverse transcriptase inhibitor, in combination with zidovudine for human immunodeficiency virus type 1 infection. In: Journal of Infectious Diseases. 1995 ; Vol. 171, No. 2. pp. 297-304.
@article{3d078691fe084b618e48c0eab05e91c0,
title = "Phase I study of atevirdine, a nonnucleoside reverse transcriptase inhibitor, in combination with zidovudine for human immunodeficiency virus type 1 infection",
abstract = "Twenty patients were enrolled in a phase I clinical trial of atevirdine, a nonnucleoside reverse transcriptase inhibitor (NNRTI), given in combination with zidovudine for treatment of human immunodeficiency virus type 1 (HIV-1) infection. Fifteen patients had received no previous antiretroviral therapy. HIV-1 isolates obtained at 6-week intervals were tested for sensitivity to atevirdine and zidovudine. Two patients developed a rash within 2 weeks of enrollment, and 1 of these developed concomitant fever and hepatitis. No hematopoietic, neurologic, or pancreatic toxicities were observed. Atevirdine had considerable initial interpatient pharmacokinetic variability. Forty- seven percent of patients treated with atevirdine plus zidovudine had increased CD4 lymphocyte counts, and HIV isolates from 62{\%} of patients remained sensitive to atevirdine after 24 weeks of therapy. Atevirdine plus zidovudine was well-tolerated. Additional studies should be done to determine the role of atevirdine in the therapy for HIV infection.",
author = "Reichman, {R. C.} and Morse, {G. D.} and Demeter, {L. M.} and L. Resnick and Y. Bassiakos and Fischl, {Margaret A} and M. Para and W. Powderly and J. Leedom and C. Greisberger and T. Nevin and K. Wood and Meehan, {P. M.} and H. Geheb and S. Cox and D. Batts and J. Timpone and A. Slack and M. Royal",
year = "1995",
month = "1",
day = "1",
language = "English",
volume = "171",
pages = "297--304",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Phase I study of atevirdine, a nonnucleoside reverse transcriptase inhibitor, in combination with zidovudine for human immunodeficiency virus type 1 infection

AU - Reichman, R. C.

AU - Morse, G. D.

AU - Demeter, L. M.

AU - Resnick, L.

AU - Bassiakos, Y.

AU - Fischl, Margaret A

AU - Para, M.

AU - Powderly, W.

AU - Leedom, J.

AU - Greisberger, C.

AU - Nevin, T.

AU - Wood, K.

AU - Meehan, P. M.

AU - Geheb, H.

AU - Cox, S.

AU - Batts, D.

AU - Timpone, J.

AU - Slack, A.

AU - Royal, M.

PY - 1995/1/1

Y1 - 1995/1/1

N2 - Twenty patients were enrolled in a phase I clinical trial of atevirdine, a nonnucleoside reverse transcriptase inhibitor (NNRTI), given in combination with zidovudine for treatment of human immunodeficiency virus type 1 (HIV-1) infection. Fifteen patients had received no previous antiretroviral therapy. HIV-1 isolates obtained at 6-week intervals were tested for sensitivity to atevirdine and zidovudine. Two patients developed a rash within 2 weeks of enrollment, and 1 of these developed concomitant fever and hepatitis. No hematopoietic, neurologic, or pancreatic toxicities were observed. Atevirdine had considerable initial interpatient pharmacokinetic variability. Forty- seven percent of patients treated with atevirdine plus zidovudine had increased CD4 lymphocyte counts, and HIV isolates from 62% of patients remained sensitive to atevirdine after 24 weeks of therapy. Atevirdine plus zidovudine was well-tolerated. Additional studies should be done to determine the role of atevirdine in the therapy for HIV infection.

AB - Twenty patients were enrolled in a phase I clinical trial of atevirdine, a nonnucleoside reverse transcriptase inhibitor (NNRTI), given in combination with zidovudine for treatment of human immunodeficiency virus type 1 (HIV-1) infection. Fifteen patients had received no previous antiretroviral therapy. HIV-1 isolates obtained at 6-week intervals were tested for sensitivity to atevirdine and zidovudine. Two patients developed a rash within 2 weeks of enrollment, and 1 of these developed concomitant fever and hepatitis. No hematopoietic, neurologic, or pancreatic toxicities were observed. Atevirdine had considerable initial interpatient pharmacokinetic variability. Forty- seven percent of patients treated with atevirdine plus zidovudine had increased CD4 lymphocyte counts, and HIV isolates from 62% of patients remained sensitive to atevirdine after 24 weeks of therapy. Atevirdine plus zidovudine was well-tolerated. Additional studies should be done to determine the role of atevirdine in the therapy for HIV infection.

UR - http://www.scopus.com/inward/record.url?scp=0028816484&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028816484&partnerID=8YFLogxK

M3 - Article

VL - 171

SP - 297

EP - 304

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 2

ER -